Clinical Trials

A Phase 1 Dose-Escalation and Cohort-Expansion Study of the Heat Shock Protein 90 Inhibitor, LAM-003, in Patients with Acute Myeloid Leukemia


Study ID
LAM Therapeutics LAM-003-HEM-CLN02

NCT Number
NCT03426605 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0704

Principle Investigator
Dr. James McCloskey

Phase
I

Sponsor
LAM Therapeutics


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now